Answer
Vemurafenib targets abnormal BRAF V600 signalling. It is licensed only when a validated test confirms this mutation and should not be used for BRAF wild-type melanoma.
Sources for this answer
- Zelboraf 240 mg Film-coated Tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.